BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33974555)

  • 1. mTOR pathway and somatostatin receptors expression intratumor-heterogeneity in ileal NETs.
    Borga C; Dal Pozzo CA; Trevellin E; Bergamo F; Murgioni S; Milanetto AC; Pasquali C; Cillo U; Munari G; Martini C; De Carlo E; Zagonel V; Guzzardo V; Pennelli G; Dei Tos AP; Vettor R; Fassan M
    Endocr Relat Cancer; 2021 Jun; 28(7):449-456. PubMed ID: 33974555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous.
    Charoenpitakchai M; Liu E; Zhao Z; Koyama T; Huh WJ; Berlin J; Hande K; Walker R; Shi C
    Virchows Arch; 2017 May; 470(5):545-552. PubMed ID: 28213807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung.
    Righi L; Volante M; Rapa I; Tavaglione V; Inzani F; Pelosi G; Papotti M
    Endocr Relat Cancer; 2010 Dec; 17(4):977-87. PubMed ID: 20817788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma.
    Wang Z; Zheng T; Wu Q; Wang J; Wu C; Wang J
    Neoplasma; 2012; 59(2):137-41. PubMed ID: 22248270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.
    Pierobon M; Ramos C; Wong S; Hodge KA; Aldrich J; Byron S; Anthony SP; Robert NJ; Northfelt DW; Jahanzeb M; Vocila L; Wulfkuhle J; Gambara G; Gallagher RI; Dunetz B; Hoke N; Dong T; Craig DW; Cristofanilli M; Leyland-Jones B; Liotta LA; O'Shaughnessy JA; Carpten JD; Petricoin EF
    Clin Cancer Res; 2017 Aug; 23(16):4919-4928. PubMed ID: 28446508
    [No Abstract]   [Full Text] [Related]  

  • 6. Ileal neuroendocrine tumors show elevated activation of mammalian target of rapamycin complex.
    Geis C; Fendrich V; Rexin P; Di Fazio P; Bartsch DK; Ocker M; Quint K; Heverhagen AE
    J Surg Res; 2015 Apr; 194(2):388-393. PubMed ID: 25439321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours.
    Kasajima A; Pavel M; Darb-Esfahani S; Noske A; Stenzinger A; Sasano H; Dietel M; Denkert C; Röcken C; Wiedenmann B; Weichert W
    Endocr Relat Cancer; 2011 Feb; 18(1):181-92. PubMed ID: 21159731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression of somatostatin receptor subtypes SSTR2a, SSTR3 and SSTR5 in peripheral blood of neuroendocrine lung cancer affected patients.
    Muscarella LA; D'Alessandro V; la Torre A; Copetti M; De Cata A; Parrella P; Sperandeo M; Pellegrini F; Frusciante V; Maiello E; Merla G; Fazio VM; Vendemiale G
    Cell Oncol (Dordr); 2011 Oct; 34(5):435-41. PubMed ID: 21503779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy.
    Beelen K; Hoefnagel LD; Opdam M; Wesseling J; Sanders J; Vincent AD; van Diest PJ; Linn SC
    Int J Cancer; 2014 Sep; 135(5):1257-63. PubMed ID: 24501006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer.
    Alabdullah ML; Ahmad DA; Moseley P; Madhusudan S; Chan S; Rakha E
    J Obstet Gynaecol; 2019 May; 39(4):522-528. PubMed ID: 30712414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.
    Slaby O; Sachlova M; Bednarikova M; Fabian P; Svoboda M; Vytopilova S; Valik D; Vyzula R
    Cancer Biother Radiopharm; 2010 Apr; 25(2):237-43. PubMed ID: 20423238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
    Chen S; Nakahara T; Uchi H; Takeuchi S; Takahara M; Kido M; Dugu L; Tu Y; Moroi Y; Furue M
    Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clusterin expression in gastrointestinal neuroendocrine tumours is highly correlated with location and is helpful in determining the origin of liver metastases.
    Mourra N; Scriva A; Mansiaux Y; Gozlan S; Bennis M; Balaton A
    Histopathology; 2014 Nov; 65(5):642-50. PubMed ID: 24807631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the expression of somatostatin receptors by immunohistochemistry in neuroendocrine tumors of the small intestine.
    Pol J Pathol; 2020; 71(1):30-37. PubMed ID: 32429652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
    Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
    Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiling mTOR pathway in neuroendocrine tumors.
    Cingarlini S; Bonomi M; Corbo V; Scarpa A; Tortora G
    Target Oncol; 2012 Sep; 7(3):183-8. PubMed ID: 22890559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
    Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP
    Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer.
    Terlević R; Perić Balja M; Tomas D; Skenderi F; Krušlin B; Vranic S; Demirović A
    Ann Diagn Pathol; 2019 Feb; 38():62-66. PubMed ID: 30476894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
    Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
    Zanini S; Renzi S; Giovinazzo F; Bermano G
    Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.